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ABSTRACT 
Introduction. The BRAF V600E mutation (BRAFmt) occurring in the metastatic colorectal cancer (mCRC) patients 
is associated with poorer prognosis, in comparison to the wild-type variant of the BRAF gene (BRAFwt). Aim of 
this work was to assess the clinical efficacy of bevacizumab (BEVA) or standard chemotherapy (ChT) in the 2nd 
or further lines of treatment in mCRC BRAFmt population. 
Material and methods. MEDLINE/PubMed, Embase and Cochrane CENTRAL databases were systematically 
searched. The reference lists of relevant studies were also checked. 
Results. 6 eligible trials were identified: MOMA (BEVA ± ChT), allowing for limited overall survival (OS) assess-
ment, WJOG 6210G (BEVA + FOLFIRI), RAISE and 20050181 (FOLFIRI), PICCOLO and Spindler 2013 (irinotecan 
monotherapy). None of those trials were designed for the treatment evaluation in BRAFmt population. Available 
evidence was restricted to limited analyses in small subgroups (from a few to several dozens of patients), oc-
casionally comprising RAS gene mutation (RASmt) as well. Based on the identified studies, the comparison of 
BEVA ± ChT vs. ChT or among different ChTs in BRAFmt population was not feasible. 
In case of BEVA (MOMA), OS hazard ratio (HR) for BRAFmt vs. BRAFwt was 1.52 (95% CI: 0.79–2.89) with dif-
ference in medians equal to 12.1 months (19.2 vs. 31.3 months, respectivelly), and BRAFmt or RASmt patients 
had median OS lower by 7.9 months and median progression free survival (PFS) by 3.0 months in WJOG 6210G 
trial. In case of ChT, median PFS was lower in BRAFmt by 12–67% (HRs range: 1.01–5.3), and median OS by 
34–73% (HRs range: 1.05–5.00). 
Conclusions. Due to limited clinical evidence, assessment of further lines of treatment in BRAFmt mCRC patients 
is uncertain, however existing data consistently suggest lower effectiveness of BEVA ± ChT or ChT in BRAFmt, 
than in BRAFwt subgroup. Hopefully, combining anti-EGFR therapies with BRAF/MEK inhibitor is expected to 
improve prognosis of those patients. 
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Introduction
Substitution of valine (Val) with glutamic acid (Glu) 
in codon 600 (V600E) of the proto-oncogenic BRAF 
kinase gene that is part of the mitogen-activated protein 
kinase (MAPK or RAS-RAF-MEK-ERK) signalling 
pathway, is present in 8–12% of metastatic colorectal 
cancer (mCRC) cases, more often with right-sided 
primary tumor location [1, 2]. This pathway plays an 
essential role in the regulation of cell proliferation, 
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differentiation, survival, and apoptosis, it is also re-
sponsible for signal transduction from growth factor 
receptors, including epidermal growth factor receptor 
(EGFR) [1–3]. This point mutation leads to constitutive 
kinase phosphorylation, which drives sustained activa-
tion of MAPK signalling pathway. The mechanism of 
this process has not been fully understood, but it seems 
that cancers with such a genetic abnormality constitute 
a distinct phenotypic group [2, 4–6]. The V600E BRAF 
mutation is detected in 40–60% of sporadic cancers 
with microsatellite instability but almost never in Lynch 
syndrome (about 1%) and in tumors with KRAS and 
NRAS mutations [1, 2, 7]. However, the co-occurrence 
of BRAF aberration and microsatellite instability may 
be associated with a better prognosis by abolishing the 
opposing effects of both genetic changes [2, 7, 8]; this 
mechanism is not fully understood [2]. It is widely ac-
cepted that the presence of BRAF V600E mutation in 
patients with colorectal cancer is associated with a poor 
prognosis at any stage of the disease [1, 2], and the 
median overall survival may be up to three times lower 
compared to patients with a wild-type gene variant [9]. 
BRAF mutations other than V600 occur much less 
frequently and most likely bear no adverse prognostic 
significance [1, 2].
Most available data in mCRC patients relate to 
first-line treatment; there are no clear differences in pro-
gression-free survival (PFS) when chemotherapy alone 
is used, however, overall survival is markedly shorter 
in BRAFmt group [2, 10]. Despite the limited scientific 
evidence, bevacizumab added to FOLFOXIRI chemo-
therapy is currently the recommended molecularly tar-
geted drug in the first-line treatment of advanced disease 
[9–14]. However, according to available clinical data 
[15, 16], a response to anti-EGFR therapy (cetuximab, 
panitumumab) is unlikely, and the occurrence of the 
V600E mutation is a contraindication to such treatment 
unless it is combined with anti-BRAF therapy [7, 14]. 
There is scarce data concerning the clinical efficacy of 
further treatment lines. The aim of this study was to 
systematically review the clinical trials assessing bevaci-
zumab or irinotecan- or oxaliplatin-based chemotherapy 
in second and further treatment lines of mCRC with 
BRAF mutation.
Methods
A systematic search of MEDLINE, Embase and 
Cochrane CENTRAL databases was conducted on 
August 5, 2019. The search strategy included all 
types of studies, i.e. secondary and primary, including 
both randomized and non-randomized clinical trials, 
as well as non-controlled ones, assessing the use of 
bevacizumab or chemotherapy containing irinotecan 
or oxaliplatin in second or further treatment lines in 
advanced CRC. Studies assessing clinical efficacy (OS, 
PFS, objective response rate — ORR) in patients 
with the BRAF V600E gene mutation were included, 
encompassing comparative assessment between sought 
interventions in the target population or assessment 
in relation to patients without the BRAF mutation. 
The defined strategy also allowed to find secondary 
studies. Detailed information on the search strategy 
and systematic review is provided in the Supplemental 
materials (Tab. S1, S2, Fig. S1).
Two-stage publication selection (titles and abstracts 
analysis followed by full texts analysis) in accordance 
with the defined PICOS scheme (Tab. S2) as well as the 
assessment of study quality and risk of bias in the ROB 
2.0 [17] and ROBINS-I [18] scales were performed by 
two independently working researchers (W.S., M.H.) 
(Tab. S3). Data extraction was carried out in pairs in 
which one of the persons checked the correctness of 
the data. Doubts were discussed with the third person 
(M.K.) until consensus was reached. The above assump-
tions were pre-determined before the actual review. Pre-
senting the results, the data for BRAFmt subgroup were 
extracted, referring to BRAFwt group when possible. 
In some cases, the necessary calculations were made to 
present the result for BRAFmt vs. BRAFwt comparison 
and based on available data the relative benefit (RB), 
response rate and a difference in median survival were 
estimated. The systematic review was carried out in ac-
cordance with current Health Technology Assessment 
(HTA) guidelines of the Agency for Health Techno logy 
Assessment and Tariffs (AOTMiT, Agencja Oceny 
Technologii Medycznych i Taryfikacji) [19].
Results
As a result of the systematic review (Tab. S1), six 
primary trials (presented in six publications) were 
found: MOMA [20], WJOG 6210G [21], RAISE [22], 
20050181 [23], PICCOLO [24] and Spindler 2013 [25] 
(Fig. S1). The results of additional analysis of data from 
the PICCOLO — Seligmann 2016 study were also taken 
into account [10]. Five of the included studies [20–24] 
were randomized clinical trials (RCT), but none of 
them was specifically targeted at the population with 
BRAF mutation — determination of this mutation was 
not required by inclusion criteria, and the assessment 
of the significance of BRAF mutation was exploratory 
and included only a subgroup of patients with available 
material and genotyping results. Furthermore, each 
study in one arm used intervention not included in the 
criteria of the presented review — the combination of 
anti-EGFR or anti-VEGF drug with chemotherapy. In 
one study [20] only limited assessment of OS was pos-
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sible, including the use of BEVA with chemotherapy 
in the next treatment line after disease progression in 
the majority of patients. Only the observational study 
Spindler 2013 [25] was aimed at assessing the impact of 
BRAF mutations. Available results were sufficient only 
for analysis of clinical efficacy within a small BRAFmt 
subgroups (from several to several dozen patients), 
sometimes including RASmt [21] and referring them 
to BRAFwt population. The identified studies did 
not allow for comparative assessment of BEVA with 
chemotherapy vs. CHT or various CHTs within the 
BRAFmt population. No systematic reviews were found 
assessing the use of the given intervention in further 
treatment lines. The characteristics of the included 
trials are presented in Table S4 and the main results are 
summarized in Table 1. No meta-analyzes of the results 
were performed due to high clinical heterogeneity. 
Bevacizumab (BEVA) + chemotherapy
In the MOMA trial (Cremolini 2019) [20], 232 pa-
tients with mCRC were randomized to one of two pro-
tocols: 8 cycles of first-line induction therapy with 
FOLFOXIRI + BEVA, followed by maintenance 
therapy continued to disease progression — BEVA or 
BEVA + metronome chemotherapy (capecitabine and 
cyclophosphamide). Central determination of BRAF 
(exon 15 [V600E] assessment with use of Matrix-Assisted 
Laser Desorption/Ionization Time-of-Flight MassAR-
RAY system or RAS gene mutations was performed 
in 203 patients, and in 20 (10%) patients mutated 
BRAF status was detected. During a median follow-up 
of 47.8 months, a total of 210 patients progressed 
and 152 (72%) received next treatment line, of which 
91 (60%) were re-treated with BEVA + FOLFOXIRI, 
and 31 (20%) — BEVA + FOLFIRI/FOLFOX, and 
3 (2%) — BEVA + fluorouracil. In total, BEVA was 
used in 82% of patients receiving the subsequent treat-
ment line. Therefore, overall survival (OS) analysis 
also included the use of BEVA in the second treatment 
line, however, it can be assumed that the observation 
concerned a maximum of approximately 11 BRAFmt 
patients who had progressed and received BEVA again 
in the next line. In the BRAFmt population, the median 
OS was 19.2 months and was significantly lower than in 
RASwt and BRAFwt patients (N = 36) — 31.3 months 
(difference of 12.1 months), similarly to RASmt 
(N = 150) — 24.9 months (difference of 6.4 months). 
In the whole group, the risk of death at a given time 
point was higher for BRAFmt compared to BRAFwt and 
RASwt, but the difference did not reach the statistical 
significance threshold: HR = 1.52 (95% CI: 0.79–2.89), 
P = 0.208 [20] (Fig. 1.).
The evaluation of bevacizumab in further treatment 
lines was also carried out in a randomized West Japan 
Oncology Group (WJOG 6210G) study (Shitara 2016) 
[21], which included patients with mCRC or inoperable, 
locally advanced CRC, with clinically or radiologically 
confirmed progression during or up to 3 months after 
the last dose of first-line chemotherapy with fluoropy-
rimidine, oxaliplatin and bevacizumab. In addition, it 
was required to exclude KRAS gene mutation (KRASwt) 
in exon 2 (codon 12 or 13) in the central or local evalu-
ation of paraffin-embedded tumor tissue. The study 
included 121 patients who were randomized to receive 
BEVA + FOLFIRI or panitumumab + FOLFIRI. Two 
patients in each group were excluded from further ef-
ficacy analysis due to failure to meet inclusion criteria. 
After progression, 77.8% of patients received another 
line of treatment, of which 34.1% received bevacizumab. 
In addition, 109 patients underwent extended genetic 
profiling covering KRAS and NRAS gene mutations 
— exon 2 (codons 12 and 13), exon 3 (codons 59, 61, 
117 and 146) and BRAF — exon 15 (codon 600) using 
next-generation sequencing (NGS) of circulating tumor 
DNA in serum. BRAF gene mutation was detected in 
5 (4.6%) patients and RAS genes mutations in 14 (12.8%) 
patients. The results are presented in a way that allows 
comparison of the combined subgroup with BRAF or 
RAS mutation with tumors without mutations in the 
tested genes (wild-type). Among BRAFmt or RASmt 
patients receiving BEVA + FOLFIRI treatment in the 
second line (N = 11), the median OS was 8.2 months 
(95% CI: 6.0–13.7) and was 7.9 months lower compared 
to wild type subgroups (N = 44) — 16.1 months (95% 
CI: 12.7–21.1). The median PFS was lower by approxi-
mately 3 months in the BRAFmt and RASmt groups: 
3.7 months (95% CI: 1.8–6.0) vs. 6.7 months (95% 
CI: 5.4–9.4), respectively. The authors also reported 
that among patients with measurable disease receiving 
BEVA + FOLFIRI, the objective response rate in the 
BRAFmt or RASmt subgroup was 18.2% and 2.6% in 
non-mutated patients, respectively. The available data 
did not allow further calculations, and when interpret-
ing the results it should also be considered that in the 
BEVA + FOLFIRI group only 3 patients achieved an 
objective response [21].
Chemotherapy
The assessment of chemotherapy in further treat-
ment lines in patients with mCRC harboring BRAF 
mutation was based on four clinical trials, two of which 
enabled the evaluation of FOLFIRI scheme: RAISE 
[22] and 20050181 [23]; and another two irinotecan 
monotherapy: PICCOLO [24] and Spindler 2013 [25].
The RAISE study evaluated the efficacy and safety 
of ramucirumab combined with FOLFIRI compared 
to placebo + FOLFIRI in patients with progression of 
mCRC during or within 6 months after the last dose of 
17
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Figure 1. Hazard ratio (HR) for overall survival (OS)
first-line therapy of metastatic disease, including bevaci-
zumab, oxaliplatin and fluoropyrimidine, if they received 
at least one cycle of therapy [22]. In total, 1,072 patients 
were included, of which exploratory assessment of the 
effect of RAS and BRAF mutations in the tumor tissue 
on the clinical effectiveness of the intervention was 
possible in 912 patients, and BRAFmt (V600E) was 
detected in 41 (4.5%) patients. Among patients receiv-
ing FOLFIRI chemotherapy alone, the median OS 
(4.2 months) was 11.3 months lower in BRAFmt patients 
(N = 21), compared to BRAFwt and RASwt groups 
(N = 143) — 15.5 months, and 7.3 months compared 
to RASmt patients (N = 294) — 11.5 months. Similarly, 
the median PFS was 2.7 months in BRAFmt patients 
compared to 5.7 months in BRAFwt and RASwt patients 
and 4.3 months in RASmt patients [22].
The 20050181 trial was another study enabling the 
evaluation of the FOLFIRI regimen in further treat-
ment lines in patients with mCRC harboring BRAF 
mutation [23]. A total of 1,186 patients who progressed 
during or within 6 months after completing the first 
line FU-containing chemotherapy were randomized 
to panitumumab + FOLFIRI or FOLFIRI. Of these, 
1,014 (85%) patients had assessed RAS mutations, and 
then among 421 RASwt patients, 45 (11%) were found 
to have BRAFmt. A total of 638 (54%) patients had RAS 
or BRAF mutations. Extended genetic diagnostics of 
paraffin-embedded tumor tissue in patients with normal 
exon 2 of the KRAS gene included Sanger sequencing 
of exon 3 (codons 59/61) and 4 (codons 117/146) of the 
KRAS gene; exon 2 (codons 12/13), 3 (codons 59/61) 
and 4 (codons 117/146) of the NRAS gene and exon 
15 (codon 600) of the BRAF gene.
The authors of 20050181 study performed an explor-
atory analysis of clinical efficacy depending on the BRAF 
status. Among patients treated with FOLFIRI, the medi-
an OS was lower by 9.7 months in patients with BRAFmt 
and RASwt tumors (N = 23) — 5.7 months, compared 
to BRAFwt and RASwt (N = 190) — 15.4 months: 
HR = 5.00 (95% CI: 3.03–7.69) (Fig. 1). Similarly, 
the median PFS in BRAFmt and RASwt group was 
1.8 months, e.g. 3.7 months lower than in BRAFwt and 
RASwt groups — 5.5 months: HR = 3.23 (95% CI: 
1.96–5.26) (Fig. 2). In both cases, the observed diffe-
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Figure 2. Hazard ratio (HR) for progression-free survival (PFS)
rences depending on the presence of BRAF mutations 
were statistically significant. 
Another two trials evaluated irinotecan-based che-
motherapy in the further treatment lines of advanced 
CRC with BRAF gene mutation. PICCOLO RCT 
included patients with inoperable, locally advanced, or 
metastatic CRC with prior progression during or after 
fluoropyrimidine-containing chemotherapy. Almost 
all patients had previously received oxaliplatin. After 
protocol amending, only patients with wild-type 12, 
13 and 16 codons of KRAS gene were recruited (no prior 
anti-EGFR therapy was required). Finally, the analysis 
included 460 patients randomly assigned to receive pani-
tumumab + irinotecan or irinotecan alone [24]. Further 
pyrosequencing of available paraffin-embedded tumor 
tissue was also carried out including codon 146 of KRAS 
gene, codon 12, 13 and 61 of NRAS gene, codon 542, 
545, 546 and 1047 of PIK3CA gene and codon 600 of 
BRAF gene. Mutations in the BRAF gene were detect-
ed in 68 (14.8%) patients. OS in patients with BRAF 
gene mutation receiving irinotecan alone (N = 31) was 
significantly shorter compared to the group with wild 
type of all of the genes listed (BRAFwt, RASwt and 
PIK3CAwt) (N = 163): HR = 1.56 (95% CI: 1.03–2.37), 
P = 0.035. This study also assessed objective response 
rate (ORR) according to RECIST criteria, which was 
twice lower in BRAFmt patients compared to all-wt: 
2 (6.5%) vs. 20 (12.3%); RB = 0.53 (95% CI: 0.13–2.14), 
however with no statistical significance (P = 0.3688) [24]. 
In addition, Seligmann et al. [10] assessed the effect of 
BRAF mutation on the effectiveness of irinotecan mono-
therapy based on patients-level data from the PICCOLO 
study, considering the entire population, regardless of 
KRAS mutation status. The analysis included 459 patients 
with available results of BRAF mutation assessment, 
among which in 40 patients V600E mutation was found. 
Median OS in BRAFmt individuals was 3.5 months lower 
compared to the BRAFwt group: 6.7 vs. 10.2 months, 
but the difference did not reach statistical signifi-
cance: HR = 1.21 (95% CI: 0.84–1.76). PFS medians 
were similar: 3.5 vs. 4.0 months; HR = 1.01 (95% CI: 
0.69–1.49), while ORR probability was lower by 44%, 
but not reaching statistical significance: 5.0% vs. 8.1%, 
OR = 0.56 (95% CI: 0.13–2.49); P = 0.45.
The last analyzed trial was the non-randomized study 
— Spindler 2013 [25], evaluating the effect of KRAS 
and BRAF gene mutations on the outcomes in mCRC 
patients receiving irinotecan monotherapy in the se-
cond line (in prospective and retrospective cohort). The 
study included 110 patients in the prospective cohort, 
of which in 97 patients BRAF mutation status of tumor 
tissue was evaluated, with 8 (7%) positive results; and 
111 patients in the retrospective cohort, among whom 
109 were genotyped and BRAFmt was detected in 8 (8%) 
subjects. Assessment of mutation in 600 codon of BRAF 
gene was performed with the use of Amplification Re-
fractory Mutation System-Quantitative PCR of DNA 
isolated from paraffin-embedded tumor tissue. 
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In the prospective cohort, HR for OS in BRAFmt 
(N = 8) vs. BRAFwt (N = 89) was 3.33 (95% CI: 0.96–
–11.11), while in the retrospective cohort — 1.05 (95% 
CI: 0.45–2.50) in 8 and 101 patients, respectively. Sim-
ilarly, the risk of progression or death (PFS analysis) 
was higher in BRAFmt patients in both the prospective 
(HR = 3.57 [95% CI: 0.99–12.50]) and the retrospective 
cohort (HR = 1.79 [95% CI: 0.70–4.54]), however with 
no statistical significance. In the multivariate analysis 
considering age, performance status (PS) and BRAF 
and KRAS genes mutational status, the presence of 
BRAF mutations was associated with significantly worse 
prognosis: HR = 4.3 (95% CI: 1.7–10.6), P = 0.002, for 
comparison BRAFmt vs. BRAFwt in OS analysis (Fig. 1) 
and HR = 5.3 (95% CI: 2.1–13.0), P = 0.0002 in PFS 
analysis (Fig. 2). No BRAFmt patient achieved the ob-
jective response compared to 14% of BRAFwt patients 
in the prospective cohort and 15% in the retrospective 
cohort, but these differences did not reach statistical 
significance [25].
Risk of bias assessment
Five RCTs were included in the systematic review 
[20–24], however, the randomization did not refer to the 
subject of this review: BRAF gene mutational status was 
neither an inclusion criterion nor a stratification factor 
of randomization, genetic analysis was performed only 
in part of included patients, and the analysis of BRAF 
mutation impact was exploratory. These studies were 
not designed to compare interventions that BRAFmt 
patients were randomized to, and one of the trial arms 
included intervention whose assessment was not the 
purpose of this review (panitumumab + FOLFIRI [21], 
ramucirumab + FOLFIRI [22], panitumumab + irino-
tecan [24]). In one study [20] only limited inference 
based on OS assessment was possible due to the fact that 
observation within this endpoint also included BEVA in 
the subsequent treatment line after disease progression 
used in the majority of patients. Ultimately, in these 
RCTs, it was only possible to assess clinical efficacy with-
in one study arm among patients with a known BRAF 
mutation and to refer these results to patients with a wild 
genotype. Accordingly, it was considered that in the 
context of presented study it would be appropriate to 
assess the risk of bias using a scale for non-randomized 
trials, as it will allow taking into account the baseline 
differences in demographic and clinical characteristics 
resulting from the lack of effective randomization. Table 
S3 presents the result of the risk of bias assessment of all 
6 publications included in the systematic review in the 
ROBINS-I scale. The risk of bias was generally high, and 
most of the limitations found resulted from the analysis 
of outcomes only in subgroups distinguished based on 
BRAF gene mutational status, for which many significant 
data were not presented in publications yet. Considering 
the construction of the ROBINS-I scale, such a severe 
limitation in the interfering factors domain translates 
into a critically high risk in the overall assessment of 
the likelihood of endpoints reliability, regardless of 
the result of the assessment in other domains in the 
scale. An exception was the additional analysis in the 
PICCOLO study [10], in which the use of appropriate 
statistical adjustments allowed to partially eliminate 
the risk of bias associated with the uneven distribution 
of prognostic factors between groups — therefore the 
cumulative risk of bias was assessed as high.
Discussion
According to published reports, the BRAF mutation 
is associated with a significantly reduced survival of 
colorectal cancer patients receiving chemotherapy, both 
in the early and advanced stages [26]. While some evi-
dence is available on the efficacy of 1st line treatment in 
advanced disease, there is limited data regarding further 
treatment. To our knowledge, this is the first published 
systematic review of available evidence assessing the 
efficacy of bevacizumab and chemotherapy in 2nd and 
further treatment lines of advanced colorectal cancer 
with the BRAF V600E mutation.
Although the presented review included predomi-
nantly RCTs, the available results only allowed for as-
sessment of clinical efficacy within particular treatment 
arms, and the comparison did not relate to different 
interventions in the BRAFwt population (presence of 
BRAF mutation or even a requirement for genetic evalu-
ation of this genetic abnormality were not an inclusion 
criterion in any of the RCTs), but only a reference of 
the outcomes observed in subjetcs receiving the same 
intervention with the mutation to those with the wild 
gene. Therefore, the assessment of the impact of BRAF 
mutation on treatment outcomes had an exploratory 
nature and was only possible in some patients with 
available material and genetic tests performed. The 
analysis of the effect of BRAF mutation on the effec-
tiveness of irinotecan monotherapy was a goal of only 
Spindler 2013 observational study [25]. To WJOG 
6210G [21] and PICCOLO [24] (after protocol amend-
ment) trials only patients with non-mutated KRAS 
gene were enrolled. Similarly, in study 20050181 [23], 
only patients with KRASwt underwent extended ge-
netic diagnostics, including BRAF gene assessment. 
In general, control groups in RCTs included patients 
with wild genotype, according to both BRAF and RAS 
mutations (and additionally PIK3CA [24]). Only in one 
study, the extended genetic profiling was carried out 
using peripheral blood circulating tumor DNA [21], in 
others, they were performed using paraffin-embedded 
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tissue specimens. Patients with metastatic CRC were 
included in most clinical trials, and only two enrolled 
patients with inoperable, locally advanced tumors 
[21, 24]. 
Severely limited data was found to assess the efficacy 
of bevacizumab (± CHT) in 2nd and subsequent treat-
ment lines in patients with advanced CRC harboring 
BRAF mutation. In one study (MOMA) with bevaci-
zumab in the 1st treatment line of metastatic disease only 
limited OS analysis was possible because this observation 
also included subsequent treatment lines, and most 
patients received re-treatment with bevacizumab [20]. 
However, it is estimated that up to app. 11 patients with 
the BRAF mutation were subjected to such analysis. On 
the other hand, in another study (WJOG 6210G), the 
assessment included a total of 11 patients with either 
BRAF or RAS mutation and it can be assumed that the 
former one occurred only in about 3 patients [21]. Never-
theless, in both studies, the median OS was consistently 
reduced in patients with the BRAF mutation, by 39% 
and 49%, respectively [20, 21], and the risk of death 
was 1.5 times higher [20]; similarly, the median PFS was 
reduced by 45% [21]. The data on the objective response 
rates in the bevacizumab group  were insufficient, which 
makes impossible to draw plausible conclusions.
Studies on the efficacy of chemotherapy in further 
treatment lines (FOLFIRI or irinotecan monotherapy) 
also had significant limitations but evaluated BRAFmt 
population was greater and included from 16 to 31 (40, 
taking into account the alternative analysis of PICCOLO 
study data [10]) patients in particular studies [22–25], 
a total of 91 patients (100 including [10]). When using 
FOLFIRI in one study, the median OS was 73% lower 
in the BRAFmt group and PFS by 53% [22], while in the 
other by 63% and 67%, respectively [23]. The risk of 
death at a given time point was several times higher if the 
mutation was present — five times [23], about 1.5 times 
[10, 24] and more than four times (multivariate analysis 
[25]), and the differences were statistically significant. 
Similarly, the risk of death or disease progression was 
more than three and four times higher ([23] and [25] 
— multivariate analysis, respectively), although in an 
alternative estimation of the PICCOLO study results 
there was no significant difference in PFS (median 12% 
lower, HR = 1.01 [10]).
Regarding the objective response rate, available data 
was markedly limited, in one study the incidence of this 
endpoint was almost twice lower in BRAFmt patients 
(statistically insignificant difference) [10, 24], while in 
the other study no patient with BRAF mutation ORR 
was reported [25].
Seligmann et al. [10] assessed the effect of BRAF 
mutation on the results of treatment of advanced CRC 
with standard chemotherapy using patient-level data 
from RCTs: COIN [27, 28] and FOCUS [29] (oxalipla-
tin and fluorouracil in the 1st line) and PICCOLO [24] 
(irinotecan in the 2nd line). The results of this additional 
analysis regarding the PICCOLO are presented in the 
main part of this publication. For the 1st line treatment of 
advanced disease, the authors found that the presence of 
the BRAF mutation is a significant OS prognostic factor 
(cumulative data for both RCTs: 10.8 vs. 16.4 months 
[HR = 1.49 (95% CI: 1.23–1.80); P < 0.001)], also after 
matching with respect to baseline characteristics. How-
ever, no clear impact of the mutation on PFS and ORR 
was observed. Survival after progression was also as-
sessed, defined as the time from progression to death 
among patients with disease progression; when the date 
of progression was unknown, the date of the last chemo-
therapy cycle was taken into account. Patients with the 
BRAF mutation had a shorter survival after progression 
compared to those with the wild-type gene in both 1st 
line studies (COIN and FOCUS), the results for both 
clinical trials: 3.2 vs. 8.6 months; HR = 1.72 (95% CI: 
1.35–2.19), P < 0.001 [10]. It is worth noting that sig-
nificantly fewer BRAFmt patients received subsequent 
treatment line: 33% vs. 51%, P < 0.001; and a signifi-
cantly higher percentage of BRAFmt patients with rapid 
progression (< 6 months) was observed in both the 1st 
and 2nd treatment line — 36.5% compared to — 21.9% 
in non-mutated patients; P < 0.001 [10]. 
It should be noted that inference based on the col-
lected data is subject to uncertainty, due to the small 
size of BRAFmt population, and on the other hand 
with methodological limitations of included trials. In 
addition, the generally high risk of systematic error in 
the included studies greatly limits conclusions of the 
analysis. This is mainly due to the nature of the analyzes 
that were only possible when the included studies were 
treated as single-arm. It should be noted that the result 
of the assessment in the other domains of the ROB-
INS-I scale was better, although this does not change 
the overall assessment of systematic error risk. The 
clinical heterogeneity of the trials (especially in terms of 
interventions used) prevents proper data synthesis and 
may affect the interpretation and the ability to relate 
the review results to the target population of metastatic 
colorectal cancer patients. 
Despite the aforementioned numerous limitations, 
the analysis quite clearly indicates lower effectiveness 
of evaluated interventions (bevacizumab ± chemo-
therapy or chemotherapy) in BRAFmt patients. In 
this group, none of the studied therapies were as ef-
fective as in BRAFwt population. The advantage of 
this systematic review is the extended search, which 
was carried out in 3 databases and also included 
non-randomized studies to comprehensively assess the 
effectiveness of the examined intervention. However, 
gray literature not being indexed in medical databases 
and ongoing research were not included which could 
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For the reasons given above, it is suggested that in 
patients with this molecular disorder, 1st line systemic 
treatment should be as intensive as possible (at least 
doublet or triplet chemotherapy, i.e. FOLFOXIRI 
regimen) preferably with the addition of bevacizumab. 
The data on the value of subsequent line therapies 
are extremely scarce, but the efficacy of chemotherapy 
and anti-angiogenic drugs appears to be low, as con-
firmed by this systematic review. 
After successes in melanoma patients, BRAF tyro-
sine kinase inhibitors appeared to be the natural choice 
for next-line therapy, especially in combination with 
MEK inhibitors, but early phase clinical trials were 
disappointing [33]. Some optimism was brought only 
by attempts to use triple therapy additionally containing 
anti-EGFR antibody. The results of the BEACON phase 
III study dedicated to previously treated patients with 
BRAF V600E mutation have been recently published. 
Combination of cetuximab with a BRAF inhibitor 
encorafenib, as well as triple therapy containing an ad-
ditional MEK inhibitor binimetinib, have been shown 
to increase overall survival and time to the quality of life 
deterioration compared to cetuximab combined with 
irinotecan-based chemotherapy [32, 37].
Another potentially very effective treatment method 
may be anti-PD1 immunotherapy or a combination of 
anti-PD1 and anti-CTLA4 because BRAF V600E mutation 
quite often coexists with microsatellite instability, which is 
a favorable predictor for this treatment [38]. Available data, 
however, come from phase II non-controlled studies, and 
patients with BRAF V600 mutation were a minority [39].
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Table S2. PICOS scheme
Parameter Inclusion criteria
Population Adults with advanced CRC and assessed BRAF 
(V600E) status, progression after first-line 
treatment of advanced disease
Intervention Bevacizumab (± CHT) in 2nd or further 
treatment line due to advanced disease 
Oxaliplatin- or irinotecan-based 
chemotherapy regimens in 2nd or further 
treatment line due to advanced disease 
Comparison As above or none
Outcomes Overall survival (OS)
Progression-free survival (PFS)
Objective response rate (ORR)
Studies enabling comparative assessment 
of sought interventions in the BRAFmt 
population or relating their effectiveness to 
BRAFwt patients were included
Study design Randomized, controlled clinical trials, 
controlled or non-controlled non-randomized 
studies, published in full-text in English or 
Polish
Systematic reviews published in English or 
Polish
Table S1. Search strategy
# Query
PubMED
#2 advanced OR metastatic
#3 colon cancer OR colorectal cancer
#4 (#2 AND #3)




#11 (#7 OR #8 OR #9 OR #10)
#13 BRAF
#16 (bevacizumab OR FOLFOXIRI OR FOLFIRI OR FOLFOX OR 
oxaliplatin OR irinotecan)
#17 (#4 AND #16)
#18 (#17 AND #11)
#20 (#13 AND #17)
#22 (#18 OR #20)
Cochrane
#1 advanced OR metastatic in Trials
#2 [mh „colorectal neoplasms”] OR „colon cancer” in Trials
#3 #1 AND #2 in Trials
#4 bevacizumab OR FOLFOXIRI OR FOLFIRI OR FOLFOX OR 
oxaliplatin OR irinotecan in Trials
#5 #3 AND #4 in Trials
#6 BRAF in Trials
#7 #6 AND #5 in Trials
#8 #7 OR #5 in Trials
Embase
#1 (advanced:de OR metastatic:de) AND [embase]/lim
#2 (‚colon cancer’:de OR ‚colorectal cancer’/exp) AND 
[embase]/lim
#3 (‚bevacizumab’:de OR folfoxiri:de OR ‚folfiri’:de OR 
‚folfox’:de OR ‚oxaliplatin’:de OR ‚irinotecan’:de) AND 
[embase]/lim
#4 #1 AND #2
#5 #3 AND #4
#6 [randomized controlled trial]/lim AND [embase]/lim
#7 random*:ab,ti AND [embase]/lim
#8 controlled:ab,ti AND [embase]/lim
#9 randomization:de AND [embase]/lim
#10 #6 OR #7 OR #8 OR #9
#11 #5 AND #10
#12 braf AND [embase]/lim
#13 #5 AND #12
#14 #11 OR #13
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The risk of bias on the ROBINS-I scale can be assessed as (in order from lowest to highest): low, moderate, serious and critical, and in the absence of relevant 
information: unspecified. The total risk error rating is not higher than the lowest among the results in individual domains. 
Figure S1. Search results. List of excluded studies at the stage of full texts analysis along with the reasons for exclusion is 
available on request
26














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Marcin Kaczor et al., Bevacizumab or standard chemotherapy in previously treated patients with metastatic colorectal cancer
St
u
d
y 
 
n
am
e
St
u
d
y 
ty
p
e 
 
an
d
 lo
ca
ti
o
n
In
te
rv
en
ti
o
n
C
o
m
p
ar
at
o
r
Po
p
u
la
ti
o
n
a
To
ta
l n
u
m
b
er
/ 
/n
u
m
b
er
  
an
al
yz
ed
  
fo
r 
m
u
ta
ti
o
n
/ 
/B
RA
Fm
t 
 
n
u
m
b
er
O
b
se
rv
at
io
n
  
p
er
io
d
,  
en
d
p
o
in
ts
Fu
n
d
in
g
20
05
01
81
* 
[2
3]
RC
T,
  
no
n-
bl
in
de
d
m
ul
ti
ce
nt
er
, 
in
te
rn
at
io
na
l
FO
LF
IR
I (
ir
in
ot
ec
an
 
18
0 
m
g/
m
2  
iv
 +
 f
ol
in
ic
 a
ci
d 
40
0 
m
g/
m
2 
iv
 o
r 
le
vo
fo
lin
at
e 
20
0 
m
g/
m
2  
iv
 +
 fl
uo
ro
ur
ac
il 
40
0 
m
g/
m
2  
bo
lu
s 
iv
 +
 fl
uo
ro
ur
ac
il 
24
00
 m
g/
m
2  
as
 a
 c
on
ti
nu
ou
s 
in
fu
si
on
 
ov
er
 2
 d
ay
s)
Pa
n
it
u
m
u
m
ab
 
(6
.0
 m
g/
kg
 in
 6
0 
m
in
 +
 n
ex
t 
in
 3
0 
m
in
 in
 s
ub
se
qu
en
t 
in
fu
si
on
s)
 +
 n
ex
t 
FO
LF
IR
I (
ir
in
ot
ec
an
 
18
0 
m
g/
m
2  
iv
 +
 fo
lin
ic
 a
ci
d 
40
0 
m
g/
m
2 
iv
 o
r l
ev
of
ol
in
at
e 
20
0 
m
g/
m
2  i
v 
+
 fl
uo
ro
ur
ac
il 
40
0 
m
g/
m
2  
bo
lu
s 
iv
  
+
 fl
uo
ro
ur
ac
il 
24
00
 m
g/
m
2 
as
 a
 c
on
ti
nu
ou
s 
in
fu
si
on
 
ov
er
 2
 d
ay
s)
m
C
RC
, p
ro
gr
es
si
on
 a
ft
er
 
flu
or
op
yr
im
id
in
e-
ba
se
d 
C
TH
11
86
/4
21
c /
45
M
ed
ia
n 
48
 w
ks
.
I: 
O
S,
 P
FS
 
II:
 o
bj
ec
ti
ve
 r
es
po
ns
e 
ra
te
b  
an
d 
du
ra
ti
on
, 
sa
fe
ty
, P
RO
s 
A
m
ge
n 
In
c
PI
C
C
O
LO
 [
24
]
RC
T,
  
no
n-
bl
in
de
d
60
 s
it
es
 in
 t
he
 
U
K
Pa
n
it
u
m
u
m
ab
 (9
 m
g/
kg
 iv
) 
 
+
 ir
in
o
te
ca
n
 (3
50
 m
g/
m
2 ;
  
if 
ag
e 
>
 7
0 
ye
ar
s 
or
 p
er
fo
rm
an
ce
 
st
at
us
 2
 —
 3
00
 m
g/
m
2 )
 (
q3
w
)
Ir
in
o
te
ca
n
 (3
50
 m
g/
m
2 ;
  
if 
ag
e 
>
 7
0 
ye
ar
s 
 
or
 p
er
fo
rm
an
ce
 s
ta
tu
s 
2 
—
 3
00
 m
g/
m
2 )
 (
q3
w
)
m
C
RC
 o
r 
lo
ca
lly
 
ad
va
nc
ed
 in
op
er
ab
le
 
C
RC
, p
ro
gr
es
si
on
 a
ft
er
 
flu
or
op
yr
im
id
in
e-
ba
se
d 
C
TH
, n
o 
pr
ev
io
us
 a
nt
i-
EG
FR
 t
he
ra
py
46
0/
bd
./6
8 
(in
 a
ll 
KR
A
S c
.1
2–
13
,6
1 
w
t)
A
dd
it
io
na
l a
na
ly
si
s 
—
 ir
in
ot
ec
an
 [
10
]:
 
51
1/
45
9/
40
M
ed
ia
n 
of
 t
re
at
m
en
t 
cy
cl
es
: 4
 (
ra
ng
e:
 0
–2
8)
I: 
O
S 
II:
 P
FS
, o
bj
ec
ti
ve
 
re
sp
on
se
 r
at
eb
, P
RO
s,
 
sa
fe
ty
 (
qu
es
ti
on
na
ir
e:
 
EO
RT
C
 Q
LQ
-C
30
)
C
an
ce
r 
Re
se
ar
ch
 U
K,
 
A
m
ge
n 
In
c.
Sp
in
dl
er
 
20
13
 [
25
]
N
on
-R
C
T,
 
pr
os
pe
ct
iv
e-
 
-r
et
ro
sp
ec
ti
ve
,
si
ng
le
 c
en
te
r 
(D
en
m
ar
k)
Ir
in
o
te
ca
n
 (b
ot
h 
co
ho
rt
s:
 
35
0 
m
g/
m
2 )
 (
q3
w
)
–
m
C
RC
, 2
nd
 li
ne
 t
re
at
m
en
t 
Pr
os
pe
ct
iv
e 
co
ho
rt
 
—
 1
10
/9
7/
8 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
 
—
 1
11
/1
09
/8
 
Pr
os
pe
ct
iv
e 
co
ho
rt
: 
m
ed
ia
n 
of
 t
re
at
m
en
t 
cy
cl
es
 4
 (
1–
15
);
 
Re
tr
os
pe
ct
iv
e 
co
ho
rt
: 
m
ed
ia
n 
of
 t
re
at
m
en
t 
cy
cl
es
 6
 (
2–
15
)
O
S,
 P
FS
, o
bj
ec
ti
ve
 
re
sp
on
se
 r
at
e,
 s
af
et
y
Tr
yg
 F
on
de
n 
an
d 
th
e 
Re
se
ar
ch
 C
ou
ns
il
H
os
pi
ta
l L
ill
eb
ae
lt
RC
T 
—
 r
an
do
m
iz
ed
 c
on
tr
ol
le
d 
tr
ia
l; 
BE
VA
 —
 b
ev
ac
iz
um
ab
; q
2w
/q
3w
 —
 d
os
e 
ad
m
in
is
te
re
d 
ev
er
y 
2 
an
d 
3 
w
ee
ks
, r
es
pe
ct
iv
el
y;
 P
RO
s 
—
 p
at
ie
nt
-r
ep
or
te
d 
ou
tc
om
es
, C
TH
 —
 c
he
m
ot
he
ra
py
*D
et
ai
le
d 
da
ta
 o
n 
th
e 
re
se
ar
ch
 m
et
ho
do
lo
gy
 c
om
e 
fr
om
 t
he
 m
ai
n 
pu
bl
ic
at
io
ns
 t
ha
t 
w
er
e 
no
t 
in
cl
ud
ed
 a
t 
th
e 
st
ag
e 
of
 r
es
ea
rc
h 
se
le
ct
io
n 
du
e 
to
 t
he
 la
ck
 o
f 
re
su
lt
s 
re
la
te
d 
to
 t
he
 a
na
ly
si
s 
—
 R
A
IS
E 
[3
4]
, 2
00
50
18
1 
[3
5]
a D
et
ai
le
d 
po
pu
la
ti
on
 d
at
a 
fo
r 
th
e 
su
bg
ro
up
s 
an
al
yz
ed
 w
as
 n
ot
 a
va
ila
bl
e
b T
um
or
 a
ss
es
sm
en
t 
ac
co
rd
in
g 
to
 t
he
 R
EC
IS
T 
cr
it
er
ia
 1
.1
 
c R
A
Sw
t 
pa
ti
en
ts
Ta
b
le
 S
4 
co
n
t.
 C
h
ar
ac
te
ri
st
ic
s 
o
f 
in
cl
u
d
ed
 c
lin
ic
al
 t
ri
al
s
